MiMedx Group, Inc. (MDXG)
3.91
-0.02
(-0.51%)
USD |
NASDAQ |
Oct 23, 16:00
3.905
0.00 (0.00%)
After-Hours: 20:00
MiMedx Group Enterprise Value : 451.15M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 451.15M |
| October 22, 2026 | 454.06M |
| October 21, 2026 | 426.38M |
| October 20, 2026 | 497.78M |
| October 19, 2026 | 519.64M |
| October 16, 2026 | 526.93M |
| October 15, 2026 | 563.36M |
| October 14, 2026 | 566.27M |
| October 13, 2026 | 564.81M |
| October 12, 2026 | 585.22M |
| October 09, 2026 | 561.90M |
| October 08, 2026 | 554.61M |
| October 07, 2026 | 553.16M |
| October 06, 2026 | 554.61M |
| October 05, 2026 | 544.41M |
| October 02, 2026 | 550.24M |
| October 01, 2026 | 557.53M |
| September 30, 2026 | 560.44M |
| September 29, 2026 | 561.90M |
| September 28, 2026 | 563.36M |
| September 25, 2026 | 561.90M |
| September 24, 2026 | 567.73M |
| September 23, 2026 | 576.47M |
| September 22, 2026 | 599.79M |
| September 21, 2026 | 582.30M |
| Date | Value |
|---|---|
| September 18, 2026 | 576.47M |
| September 17, 2026 | 564.81M |
| September 16, 2026 | 570.64M |
| September 15, 2026 | 569.19M |
| September 14, 2026 | 557.53M |
| September 11, 2026 | 547.33M |
| September 10, 2026 | 551.70M |
| September 09, 2026 | 563.36M |
| September 08, 2026 | 561.90M |
| September 04, 2026 | 547.33M |
| September 03, 2026 | 526.93M |
| September 02, 2026 | 544.41M |
| September 01, 2026 | 540.04M |
| August 31, 2026 | 542.96M |
| August 28, 2026 | 537.13M |
| August 27, 2026 | 538.58M |
| August 26, 2026 | 525.47M |
| August 25, 2026 | 513.81M |
| August 24, 2026 | 503.61M |
| August 21, 2026 | 512.35M |
| August 20, 2026 | 507.98M |
| August 19, 2026 | 529.84M |
| August 18, 2026 | 513.81M |
| August 17, 2026 | 491.95M |
| August 14, 2026 | 503.61M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 273.50M |
| Perspective Therapeutics, Inc. | -49.23M |
| ABVC BioPharma, Inc. | 31.57M |
| Enovis Corp. | 2.574B |
| Edwards Lifesciences Corp. | 47.91B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.84M |
| Revenue (Quarterly) | 64.36M |
| Total Expenses (Quarterly) | 79.20M |
| EPS Diluted (Quarterly) | -0.1004 |
| Gross Profit Margin (Quarterly) | 68.50% |
| Profit Margin (Quarterly) | -23.06% |
| Earnings Yield | 1.01% |
| Operating Earnings Yield | 1.50% |
| Normalized Earnings Yield | 1.008 |